

## Clark & Elbing LLP

101 Federal Street  
Boston, MA 02110

Telephone 617-428-0200  
Facsimile 617-428-7045  
617-428-7046

**Date:** June 13, 2005

**To:** Examiner Kashal

**Facsimile No:** 571-273-0769

**From:** Michael J. Belliveau

**Re:** U.S. Patent Application Serial No. 10/600,272

**Pages:** 4

**Message:** Per our telephone conversation of last week, enclosed please find a proposed claim amendment in connection with the above-referenced case.

---

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

---

U.S. Patent Application Serial No. 10/600,272

Filed June 20, 2003

Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston

MAMMALIAN IAP GENE FAMILY, PRIMERS, PROBES

AND DETECTION METHODS

Our Reference: 07891/003006

✱

Proposed claim amendments

✱

1. (Currently amended) A substantially pure polypeptide consisting of a sequence having at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 25 a ~~sequence selected from the group consisting of SEQ ID NOs: 24, 25, 26, and 27, amino acids 255-322 of SEQ ID NO: 40, and amino acids 241-308 of SEQ ID NO: 42, wherein~~ said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.

2. (Original) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 24.

3. (Original) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 25.

4. (Cancelled) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 26.

5. (Cancelled) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 27.

6. (Cancelled) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to amino acids 255-322 of SEQ ID NO: 40.

7. (Cancelled) The polypeptide of claim 1, wherein said polypeptide has at

*Attachment to Interview Summary (Not claims)*  
✱

USSN 10/600,272

Atty Docket: 07891/003006

2.

least 95% sequence identity to amino acids 241-308 of SEQ ID NO: 42.

8. (Currently amended) A substantially pure polypeptide consisting of SEQ ID NO: 24 or SEQ ID NO: 25 ~~a sequence selected from the group consisting of SEQ ID NOs: 24, 25, 26, and 27, amino acids 255-322 of SEQ ID NO: 40, and amino acids 241-308 of SEQ ID NO: 42~~, wherein said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.

9. (Original) The polypeptide of claim 8, wherein said polypeptide has the sequence of SEQ ID NO: 24.

10. (Original) The polypeptide of claim 8, wherein said polypeptide has the sequence of SEQ ID NO: 25.

11. (Cancelled) The polypeptide of claim 8, wherein said polypeptide has the sequence of SEQ ID NO: 26.

12. (Cancelled) The polypeptide of claim 8, wherein said polypeptide has the sequence of SEQ ID NO: 27.

13. (Cancelled) The polypeptide of claim 8, wherein said polypeptide has the sequence of amino acids 255-322 of SEQ ID NO: 40.

14. (Cancelled) The polypeptide of claim 8, wherein said polypeptide has the

*Attachment to interview summary (Not Claiming)*

USSN 10/600,272

Atty Docket: 07891/003006

3.

sequence of amino acids 241-308 of SEQ ID NO: 42.

15. (Currently amended) A substantially pure polypeptide comprising SEQ ID NO: 24 or SEQ ID NO: 25 ~~a sequence selected from the group consisting of SEQ ID NOs: 24, 25, 26, and 27, amino acids 255-322 of SEQ ID NO: 40, and amino acids 241-308 of SEQ ID NO: 42~~, wherein said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.

16. (Original) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of SEQ ID NO: 24.

17. (Original) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of SEQ ID NO: 25.

18. (Cancelled) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of SEQ ID NO: 26.

19. (Cancelled) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of SEQ ID NO: 27.

20. (Cancelled) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of amino acids 255-322 of SEQ ID NO: 40.

21. (Cancelled) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of amino acids 241-308 of SEQ ID NO: 42.

*Attachment to Interview Summary (Not claims)*